Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

712 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. Montironi R, et al. Among authors: moch h. Curr Drug Targets. 2016;17(7):750-6. doi: 10.2174/1389450117666151209144649. Curr Drug Targets. 2016. PMID: 26648079 Review.
Bladder cancer: molecular determinants of personalized therapy.
Lopez-Beltran A, Santoni M, Massari F, Ciccarese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C, Montironi R. Lopez-Beltran A, et al. Among authors: moch h. Curr Drug Targets. 2015;16(2):115-24. doi: 10.2174/1389450116666150204115756. Curr Drug Targets. 2015. PMID: 25654736 Review.
Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M. Montironi R, et al. Among authors: moch h. Curr Drug Targets. 2016;17(7):777-82. doi: 10.2174/1389450117666160217123304. Curr Drug Targets. 2016. PMID: 26898309 Review.
Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?
Ciccarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F. Ciccarese C, et al. Among authors: moch h. Curr Drug Metab. 2017;18(8):692-699. doi: 10.2174/1389200218666170518163549. Curr Drug Metab. 2017. PMID: 28524006 Review.
Molecular foundations for personalized therapy in prostate cancer.
Fisher KW, Montironi R, Lopez Beltran A, Moch H, Wang L, Scarpelli M, Williamson SR, Koch MO, Cheng L. Fisher KW, et al. Among authors: moch h. Curr Drug Targets. 2015;16(2):103-14. doi: 10.2174/1389450115666141229154500. Curr Drug Targets. 2015. PMID: 25547910 Review.
Oncotargets in different renal cancer subtypes.
Moch H, Montironi R, Lopez-Beltran A, Cheng L, Mischo A. Moch H, et al. Curr Drug Targets. 2015;16(2):125-35. doi: 10.2174/1389450116666150126110632. Curr Drug Targets. 2015. PMID: 25619751 Review.
Urinary Biomarkers for Prostate Cancer.
Giunchi F, Ciccarese C, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Moch H, Massari F, Fiorentino M. Giunchi F, et al. Among authors: moch h. Curr Drug Metab. 2017 Oct 16;18(8):723-726. doi: 10.2174/1389200218666170518161140. Curr Drug Metab. 2017. PMID: 28524004 Review.
712 results